Navigation Links
UNC awarded $6.2 million renewal grant by NIH Rare Diseases Research Network
Date:10/13/2009

CHAPEL HILL The University of North Carolina at Chapel Hill has been awarded a five-year, $6.2 million renewal grant to continue its work as part of the National Institutes of Health's Rare Diseases Clinical Research Network (RDCRN).

"This additional funding will let us continue our discovery of rare disease-causing gene mutations, which has already culminated in a clinical genetic test, but which needs to be expanded and improved," said Michael Knowles, M.D., a professor in the UNC School of Medicine's Division of Pulmonary and Critical Care Medicine and principal investigator for the RDCRN.

"It will also let us define early adverse clinical events in the infant and childhood studies led by Dr. Margaret Leigh and Dr. Stephanie Davis here at UNC. These advances in diagnostics and pathophysiology are likely to lead to earlier diagnosis and therapeutic interventions, and likely better clinical outcome."

Within the RDCRN, UNC is the lead institution in a study of rare genetic airways disorders, such as cystic fibrosis and primary ciliary dyskinesia. UNC also heads a multi-center group within the network, called the Genetic Diseases of Mucociliary Clearance Consortium (GDMCC). Other institutions in the consortium reporting to UNC include Washington University in St. Louis, The Children's Hospital in Denver, Colo., Children's Hospital & Regional Medical Center in Seattle, Wash., the National Institute of Allergy and Infectious Diseases (NIAID), Lucille Packer Children's Hospital at Stanford University, and the Hospital for Sick Children in Toronto.

In addition to Knowles, UNC faculty and staff involved in the project include Margaret Leigh, M.D., professor, and Stephanie Davis, M.D., associate professor, both in the Department of Pediatrics; Susan Minnix, a nursing education clinician who is serving as national coordinator for the consortium; and Maimoona Zariwala, Ph.D., a research assistant professor in the Department of Pathology and Laboratory Medicine.

Since its creation in 2003, the RDCRN has enrolled over 5,000 patients in 37 clinical studies in rare diseases. Patient recruitment for clinical studies is a fundamental challenge in rare diseases research because there are typically so few affected patients in any one area. The RDCRN was designed to address this problem by fostering collaboration among scientists and shared access to geographically distributed research resources. Network consortia have also established training programs for clinical investigators who are interested in rare diseases research.

Officially, a rare disease is defined as a disease or condition affecting fewer than 200,000 persons in the United States. About 6,000 such disorders have been identified, impacting an estimated 25 million Americans. Few drug companies conduct research into rare diseases since there is little chance to recoup the costs of developing treatments for such small, geographically dispersed populations.


'/>"/>

Contact: Tom Hughes
tahughes@unch.unc.edu
919-966-6047
University of North Carolina School of Medicine
Source:Eurekalert

Related biology news :

1. 12 McGill researchers awarded Canada Research Chairs
2. Anthony S. Fauci awarded Lasker Award for Public Service
3. ETH Zurich professor Ari Helenius awarded Benoist Prize
4. Nanobiosym awarded $2 million DTRA contract
5. Mustafa alAbsi Ph.D. and national team awarded major NIH grant
6. Parus Interactive Awarded Patent for Speech-Activated Remote System Management
7. $2.7 million awarded for metastatic colon cancer research
8. UCR researchers awarded nearly $1.7M to develop improved cowpea varieties
9. BIO-key(R) and Tiger IT Awarded a Follow-on Contract for Nationwide Voter / Citizen Registration in Bangladesh
10. University awarded £5M to investigate how cells communicate
11. Manomet Center awarded major NFWF grant to foster shorebird conservation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/25/2016)... --  Unisys Corporation (NYSE: UIS ) today announced the ... Airport, New York City , to help ... enter the United States using passports that ... testing of the system at Dulles last year. The system ... January 2016. --> pilot testing of the system ...
(Date:1/20/2016)... , Jan. 20, 2016 A market ... to directly benefit from the explosion in genomics knowledge. ... Howe Sound Research. A range of dynamic trends are ... - personalized medicine - pharmacogenomics - pathogen evolution ... with large markets - greater understanding of the role ...
(Date:1/13/2016)... --> --> ... report titled - Biometric Sensors Market - Global Industry Analysis, ... to the report, the global biometric sensors market was valued at ... US$1,625.8 mn by 2023, expanding at a CAGR of ... the biometric sensors market is expected to reach 1,799.6 ...
Breaking Biology News(10 mins):
(Date:2/5/2016)... 2016  In the pharmaceutical industry the medical affairs ... launch activities including the identification and engagement of key ... especially high in the oncology therapeutic area where most ... the Role of Medical Affairs in Oncology Launch Excellence ... therapies find better ways to utilize medical affairs to ...
(Date:2/5/2016)... -- Amarantus BioScience Holdings, Inc. ... products for Regenerative Medicine, Neurology and Orphan Diseases, announced ... from the US Food and Drug Administration (FDA) for ... granted orphan drug designation (ODD) by the US FDA ... Inc. (OTCQB: AMBS), a biotechnology company ...
(Date:2/4/2016)... Francisco, CA (PRWEB) , ... February 04, 2016 ... ... of enterprise talent development and compliance training, today announced an interactive FDA ... Morf Playbook™. The RAPS (Regulatory Affairs Professional Society) accredited interactive course on ...
(Date:2/4/2016)... 2016  Sangamo BioSciences, Inc. (NASDAQ: SGMO ), ... Edward Lanphier , Sangamo,s president and chief executive ... Sangamo,s ZFP Therapeutic ® development programs and an ... ET on Thursday, February 11, 2016, at the Leerink ... conference is being held in New York ...
Breaking Biology Technology: